Bioanalytical Method Development and Validation of Levetiracetam, Pantoprazole and Therapeutic Activity of Levetiracetam

DOI:

https://doi.org/10.37285/ijpsn.2022.15.3.8

Authors

  • Prathyusha Rani T Research scholar, Department of Pharmaceutics, School of pharmaceutical sciences VELS institute of science, technology and advanced studies. Pallavaram, Chennai-600117, Tamilnadu
  • AKILADEVI D Department of Pharmaceutics, School of pharmaceutical sciences VELS institute of science, technology and advanced studies. Pallavaram, Chennai-600117, tamil nad

Abstract

Background: Levetiracetam is an antiepileptic drug prescribed in the treatment of patients with seizures. This study aimed to develop a bioanalytical (HPLC) high­ performance liquid chromatography method for monitoring drug plasma levels in subjects with levetiracetam and pantoprazole as comedication.

Method: A Bioanalytical Method Development and Validation were done through High­ Performance Liquid Chromatography was developed to analyze the plasma level concentration of levetiracetam in subjects. The plasma concentrations were analyzed in 65 epileptic subjects given 250 to 1000 mg/dose of levetiracetam ranging in males 4550.72ng/mL and females 2586.48ng/mL. 

Results: The validation parameters were processed as ICH guidelines with linearity of levetiracetamwhereY=57.978X+6.6141andforpantoprazoleY=20.047X+102followedwith Inter dayandintradayprecisionon250ng/ml,450ng/ml,650ng/mlforlevetiracetamwhere

%RSD are 0.02,0.09,0.03,0.02,0.07 and 0.02 respectively, where the pantoprazole %RSD are 0.05,0.02,0.01,0.02,0.05, and0.03respectively. Therapeutic Drug Monitoring for levetiracetam with pantoprazole as comedication showed significant results where the mean serum concentration for 65 subjects who undergoing medication for period of time with achieved steady state serum concentration. The therapeutic range was found to be 25 male and 12 female subjects, further 28 subjects of both genders were under sub-therapeutic activity with no dose correction requirement.

Conclusion: The method proposed to measure levetiracetam concentration was convenient, reproducible, and specific. Therefore, randomized, controlled studies in a larger population are awaited with a wide range of dosing (250­1000mg) to correlate with the total serum concentration of the population and multiple comedications for dose adjustments to maintain the maximum safe concentration in the subject.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Levetiracetam, Pantoprazole, Epilepsy, Therapeutic Drug Monitoring

Downloads

Published

2022-06-30

How to Cite

1.
T PR, D A. Bioanalytical Method Development and Validation of Levetiracetam, Pantoprazole and Therapeutic Activity of Levetiracetam. Scopus Indexed [Internet]. 2022 Jun. 30 [cited 2024 Nov. 19];15(3). Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/2542

Issue

Vol. 15 No. 3 (2022): May-June 2022

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Abou-Khalil B, Schaich L. (2005) Long-term efficacy of levetiracetam for partial seizures. Seizure.;14:577–585.

Ben-Menachem E, Falter U. (2000)Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. ;41:1276–1283.

E. Perucca, B. E. Gidal, and E. Baltes,(2003) “Effects of antiepileptic ` comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials,” Epilepsy Research, vol. 53, no. 1-2, pp. 47–56.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D.(2004) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 27;62(8):1261-73.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D.(2004) Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy : Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 27;62(8):1252-60.

Petrusevska M, Berglez S, Krisch I, Legen I, Megušar K, Peternel L, Abrahamsson B, Cristofoletti R, Groot DW, Kopp S, Langguth P, Mehta M, Polli JE, Shah VP, Dressman J. Biowaiver(2015) Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam. J Pharm Sci. ;104(9):2676-87.

Perumal SS, Ekambaram SP, Raja S. (2014)Analytical method development and validation of simultaneous estimation of rabeprazole, pantoprazole, and itopride by reverse-phase high-performance liquid chromatography. journal of food and drug analysis. 1;22(4):520-6.

P. N. Patsalos, (2004)“Clinical pharmacokinetics of levetiracetam,” Clinical Pharmacokinetics vol. 43, no. 11, pp. 707–724.

P. N. Patsalos,(2000) “Pharmacokinetic profile of levetiracetam: toward ideal characteristics,” Pharmacology & Therapeutics, vol. 85, no. 2, pp. 77–85.

Ramadan, N. K., El-Ragehy, N. A., Ragab, M. T., & El-Zeany, B. A. (2015). Simultaneous determination of a binary mixture of pantoprazole sodium and itopride hydrochloride by four spectrophotometric methods. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 137, 463-470.

R. Grunewald,(2005) “Levetiracetam in the treatment of idiopathic ¨ generalized epilepsies,” Epilepsia, vol. 46, no. 9, pp. 154–160.

Steinhoff BJ, Trinka E, Wieser HG.(2005) Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Seizure;14:490–496.